Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Knelson, Erik H., Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, and Gerard C. Blobe. “Abstract 2674: Stroma biology identifies heparins as differentiating agents in neuroblastoma.” In Experimental and Molecular Therapeutics. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-2674.

Full Text

Liu, Yingmiao, Hongyu Tian, Gerard C. Blobe, Charles P. Theuer, Herbert I. Hurwitz, and Andrew B. Nixon. “Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.” Invest New Drugs 32, no. 5 (October 2014): 851–59. https://doi.org/10.1007/s10637-014-0129-y.

PMID
24994097
Full Text

Elderbroom, Jennifer L., Jennifer J. Huang, Catherine E. Gatza, Jian Chen, Tam How, Mark Starr, Andrew B. Nixon, and Gerard C. Blobe. “Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.” Mol Biol Cell 25, no. 16 (August 15, 2014): 2320–32. https://doi.org/10.1091/mbc.E13-09-0524.

PMID
24966170
Full Text

Meyer, Alison E., Catherine E. Gatza, Tam How, Mark Starr, Andrew B. Nixon, and Gerard C. Blobe. “Role of TGF-β receptor III localization in polarity and breast cancer progression.” Mol Biol Cell 25, no. 15 (August 1, 2014): 2291–2304. https://doi.org/10.1091/mbc.E14-03-0825.

PMID
24870032
Full Text

Bitting, Rhonda L., Patrick Healy, Patricia A. Creel, James Turnbull, Karla Morris, Sarah Yenser Wood, Herbert I. Hurwitz, et al. “A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.” Clin Genitourin Cancer 12, no. 4 (August 2014): 241–50. https://doi.org/10.1016/j.clgc.2013.11.020.

PMID
24685058
Full Text

Rangwala, Fatima, Johanna C. Bendell, Mark F. Kozloff, Christy C. Arrowood, Andrew Dellinger, Jennifer Meadows, Sandra Tourt-Uhlig, et al. “Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.” Invest New Drugs 32, no. 4 (August 2014): 700–709. https://doi.org/10.1007/s10637-014-0089-2.

PMID
24711126
Full Text

Dellinger, A. E., A. B. Nixon, and H. Pang. “Integrative pathway analysis using Graph-Based learning with applications to TCGA colon and ovarian data.” Cancer Informatics 13, no. SUPPL.4 (July 28, 2014). https://doi.org/10.4137/CIN.S13634.

Full Text

Kumar, S., C. C. Pan, J. C. Bloodworth, A. B. Nixon, C. Theuer, D. G. Hoyt, and N. Y. Lee. “Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.” Oncogene 33, no. 30 (July 24, 2014): 3970–79. https://doi.org/10.1038/onc.2013.386.

PMID
24077288
Full Text

Knelson, Erik H., Angela L. Gaviglio, Jasmine C. Nee, Mark D. Starr, Andrew B. Nixon, Stephen G. Marcus, and Gerard C. Blobe. “Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.” J Clin Invest 124, no. 7 (July 2014): 3016–31. https://doi.org/10.1172/JCI74270.

PMID
24937430
Full Text

Liu, Yingmiao, Mark D. Starr, John C. Brady, Andrew Dellinger, Herbert Pang, Bonne Adams, Charles P. Theuer, Nam Y. Lee, Herbert I. Hurwitz, and Andrew B. Nixon. “Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.” Cancer Med 3, no. 3 (June 2014): 580–91. https://doi.org/10.1002/cam4.207.

PMID
24574330
Full Text

Pages